ETFs with exposure to FibroGen, Inc. : November 20, 2017 Mon, 20 Nov 2017 17:27:48 +0000 Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to FibroGen, Inc. Here are 5 ETFs with the largest exposure to FGEN-US. Comparing the performance and risk of FibroGen, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
(Read more...)
See what the IHS Markit Score report has to say about FibroGen Inc. Wed, 15 Nov 2017 13:07:04 +0000 Short interest is low for FGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, ETFs holding FGEN are favorable, with net inflows of $3.46 billion.
FibroGen, Inc. :FGEN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017 Mon, 13 Nov 2017 14:34:22 +0000 Categories: Yahoo FinanceGet free summary analysis FibroGen, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of FibroGen, Inc. – Illumina, Inc., Acceleron Pharma Inc, Accelerate Diagnostics, Inc. and Harvard Bioscience, Inc. (ILMN-US, XLRN-US, AXDX-US and HBIO-US) that have also reported for this period. Highlights Summary ... Read more
(Read more...)
FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : November 10, 2017 Fri, 10 Nov 2017 12:58:22 +0000 Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for FibroGen, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more
(Read more...)
FibroGen reports 3Q loss Wed, 08 Nov 2017 22:31:59 +0000 The San Francisco-based company said it had a loss of 50 cents per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for ...
FibroGen Reports Third Quarter 2017 Financial Results Wed, 08 Nov 2017 21:02:00 +0000 Roxadustat NDA Filing Accepted for CFDA Review; Positive Pamrevlumab Phase 2 IPF Results Reported Conference Call and Webcast to be Held Today at 5:00 p.m. Eastern Time/2: 00 p.m. SAN FRANCISCO, Nov. 08, ...
FibroGen, Inc. to Host Earnings Call Wed, 08 Nov 2017 19:10:00 +0000 NEW YORK, NY / ACCESSWIRE / November 8, 2017 / FibroGen, Inc. (NASDAQ: FGEN ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 8, 2017 at 5:00 PM Eastern Time. ...
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.